Abstract

Nineteen tosylated acyl hydrazone derivatives were synthesized, and their inhibitory activities against monoamine oxidases (MAOs), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and β-secretase (BACE-1) were evaluated. Compound 3o was the most potent inhibitor of MAO-A, with an IC50 value of 1.54 µM, followed by 3a (IC50 = 3.35 µM). A structural comparison with 3a indicated that the 3-F group in 3o increased its inhibitory activity against MAO-A. Compound 3s was the most potent inhibitor of MAO-B, with an IC50 value of 3.64 µM, followed by 3t (IC50 = 5.69 µM). The MAO-B inhibitory activity increased in the order of 3- > 4- > 2-NO2 groups in 3s, 3t, and 3r, respectively. All the compounds weakly inhibited AChE and BChE, which retained >50% residual activity at 10 µM, except for 3a, which inhibited BChE with an IC50 value of 16.1 µM. Interestingly, 3e, 3f, and 3n inhibited BACE-1 with IC50 values of 8.63, 9.92, and 8.47 µM, respectively, which were lower than the IC50 of the quercetin reference. Compounds 3o and 3s were found to be reversible competitive inhibitors of MAO-A and MAO-B, respectively, with Ki values of 0.35 ± 0.074 and 1.97 ± 0.65 µM, respectively. Moreover, compounds 3e, 3f, and 3n were effective BACE-1 inhibitors. The lead molecules were further investigated by molecular docking studies to elucidate the binding interactions with the target enzymes.

Highlights

  • Dementia is a serious disease that predominantly affects aging patients, especially the elderly population

  • The general synthesis of 3a–t is depicted in Scheme 1

  • Compounds were synthesized starting from ethyl paraben hydrazide

Read more

Summary

Introduction

Dementia is a serious disease that predominantly affects aging patients, especially the elderly population. Alzheimer’s disease (AD) is one of the most common causes of dementia and is related to the loss of cognitive functions. The mechanism of AD pathogenesis is not fully understood, AD is principally caused by low acetylcholine (ACh) levels, oxidative stress, and β-amyloid plaque deposits [1]. Numerous studies have reported that cognitive functions are related to the cholinesterase (ChE) system, by breaking down the neurotransmitter ACh, and, ChE inhibition is effective for the treatment of AD [2]. ChE inhibitors suppress the degradation of this chemical messenger in the brain, which is important for memory and learning [3]. The cholinergic hypothesis suggests that the role played by ChE inhibitors in AD is related to neurotransmitter transfer [4]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call